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Abstract
Trigeminal Neuralgia is a clinical presentation of different diseases, defined in the last edition of the International
Classification of Headache Disorders (ICHD-3) as “Classical Trigeminal Neuralgia” and “Painful Trigeminal
Neuropathy”. In both groups typical and atypical clinical findings are present. They must be taking into consideration
for defining a correct clinical diagnosis. In addition MRI findings and other objective signs allow to disclose the
Etiology of the Trigeminal Neuralgia.
The surgical treatment offers many options: open surgery in posterior fossa, neuroablative procedures on the
trigeminal nerve, neuromodulation techniques on the trigeminal pathways.
Open surgery and neuroablative procedures are the treatments chosen in Classical Trigeminal Neuralgia and in
Painful Trigeminal Neuropathy showing pure or prevalent typical clinical findings. Instead in Painful Trigeminal
Neuropathy with pure or prevalent atypical clinical findings the neuromodulation techniques are the treatments to be
chosen.
Looking at the Literature reports and at our own experience, techniques, results, and indications of microvascular
decompression, radiofrequency thermocoagulation, glycerol rhizolysis, balloon microcompression, and sterotactic
radiosurgery of the trigeminal root are reported and discussed.
Keywords: Trigeminal neuralgia; Surgical treatment; Microvascular
decompression; Radiofrequency thermocoagulation; Glycerol
rhizolysis; Balloon microcompression; Sterotactic radiosurgery
Introduction
Trigeminal neuralgia is a painful condition of the face usually
having a clear-cut clinical presentation: evoked paroxysmal pain in one
or more unilateral trigeminal branches. The surgical treatment has
gained a chance of success superior to that applied to any other types
of chronic pain and is much more effective than the medical treatment
[1-3]. But at the condition that it is delivered to the right patient.
Actually Trigeminal Neuralgia (TN) is a clinical presentation of
different diseases, whose taxonomy has been widely discussed and
recently summarized in the last edition of the International
Classification of Headache Disorders (ICHD-3) [4]. Two subgroups of
TN are firstly indicated: Classical Trigeminal Neuralgia (CTN) and
Painful Trigeminal Neuropathy (PTN).
CTN is further divided in CTN purely paroxysmal and CTN with
concomitant persistent facial pain. This denomination encompasses
the cases classified before as primary, essential, and idiopathic
trigeminal neuralgia. Actually the surgical exploration of the
trigeminal nerve in the posterior fossa and the improvement of
neuroimaging by MRI has shown that there is an often recognizable
etiology: the neurovascular conflict.
PTN identifies the cases classified before as secondary trigeminal
neuralgia. The following subgroups are indicated: PTN attributed to
acute herpes zoster, post-herpetic trigeminal neuropathy, post-
traumatic trigeminal neuropathy, PTN attributed to Multiple Sclerosis
(MS) plaque, to space-occupying lesion, and to other disorders.
The clinical diagnostic criteria of CTN are clearly defined in a six
point list, summarizing the well-known clinical findings reported in
the literature starting from the ancient descriptions of the XVII-XVIII
century [5]:
At least three attacks of unilateral facial pain fulfilling criteria B and
C.
Occurring in one or more divisions of the trigeminal nerve, with no
radiation beyond the trigeminal distribution
• Pain has at least three of the following four characteristics:
• recurring in paroxysmal attacks lasting from fraction of a second
to 2 minutes
• severe intensity
• electric shock-like, shooting, stabbing or sharp in quality
• precipitated by innocuous stimuli to the affected side of the face
• No clinically evident neurological deficit
• Not better accounted for by another ICHD-3 diagnosis.
These are the so called “typical clinical findings”, to whom are
usually added other features: completely pain-free periods after the
attacks, refractory period after the painful paroxysms, spontaneous
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prolonged periods of remissions of the pain attacks for weeks or
months, abolition of pain by antiepileptic drugs (mainly
carbamazepine and oxacarbazepine).
It is well accepted that in some patient at the beginning or during
the history of the disease other so called “atypical clinical findings” can
appear: spontaneous pain attacks, prolonged pain aching or burning
after the paroxysms, sensory deficits in the area of pain, resistance to
the antiepileptic drugs.
For this reasons the ICHD committee introduced the definition of
“CTN purely paroxysmal” and “CTN with concomitant persistent
facial pain” in the substitution of the previous denomination of
trigeminal neuralgia type 1 and type 2 [6].
The ICDH-3 characters of CTN are related to the cases of TN
“developing without apparent cause other than neurovascular
compression”. Recently Cruccu and co-workers criticized this
definition [7]. They stressed that, although TN is a prototype of
neuropathic pain, the cases in which the conflict is absent or cannot be
demonstrated do not completely fit the grading system for the
diagnosis of definite neuropathic pain [8]. Then they proposed to
maintain in these cases the definition of “idiopathic trigeminal
neuralgia”, characterized by a “clinically established TN” diagnosis.
CTN diagnosis should be reserved to the “Etiology established TN” in
which the neurovascular conflict has been demonstrated. This is
relevant for the Neurosurgeon, first of all because most of the patients
are referred by the Neurologists or the Pain Therapists and it is
essential to have the same language. Moreover a very important
question for the Neurosurgeon arises: is it still justified the posterior
fossa exploration when MRI does not clearly show the neurovascular
conflict? We are still waiting for a convincing answer.
The same clinical findings of CTN can appear in the PTN, mainly in
the cases attributed to MS or space-occupying lesions. But it is well
recognized that in these diseases the atypical clinical findings are more
often present, and sometimes prevalent, especially in post-herpetic and
post-traumatic trigeminal neuropathies. The grading system for the
diagnosis of definite neuropathic pain in these cases is completely
satisfied because “objective signs or tests that reveal an underlying
lesion or disease of the nervous system” [8] can be easily found.
Finally the ICHD-3 classification clearly keeps separated the TN
from the “Persistent idiopathic facial pain (PFIP)”. In this disease,
previously defined as “atypical facial pain”, any surgical procedure is
contraindicated, because it is either useless or making the pain worse.
The surgical treatment of TN offers various procedures
Open surgical operations for removing the compression of the
trigeminal nerve, by eliminating the neurovascular conflict or the
tumor;
Neuroablative operations for reducing the trigeminal input:
percutaneous procedures or stereotactic radiosurgery on the
retrogasserian trigeminal root. Open surgical trigeminal rhizotomy
and tractotomy are nowadays rarely performed;
Neuromodulation procedures, such direct electrostimulation of the
peripheral trigeminal branches, the gasserian ganglion, the motor
cortex or the spinal cord [9,10], transcranial magnetic or electric
stimulation of the motor cortex [11], intrathecal drugs delivery [12],
and pulsed radiofrequency of peripheral trigeminal branches or
gasserian ganglion [13].
The pathophysiology, the clinical presentation and the etiology of
the TN give the guidelines to the surgeon for choosing the more useful
procedure in any particular case (Figure 1).
Figure 1: Guidelines for the choice of the surgical treatment.
As a general rule, microvascular decompression, percutaneous
neuroablative procedures and stereotactic radiosurgery are as much
effective as the typical clinical findings of TN are prevalent. When
atypical clinical findings, that are the clinical signs of severe trigeminal
neuropathy, are the only or the prevalent elements, neuromodulation
procedures must be preferred. They will not be described in this revue.
In this paper we will report the technique, the indications and the
results of the surgical procedures, looking at the Literature and at our
experience regarding 1,041 patients operated on by 1,197 procedures at
the Neurosurgical Department of the University and at the Pain
Therapy Division of the Molinette Hospital in Turin (Table 1).
Procedures No. of procedures
(no. of patients)
Age min-max (mean) years Period Notes
MVD 245 (239) 18-76 (56) 1981-2015 CNT: 240 (235)
MS: 5 (5)
PCA Tumor removal 23 (23) 22-76 (53) 1982-2015 Epidermoid: 7
Acoustic neu: 9
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Meningioma: 5
AAV: 1
PMC 565 (498) 34-94 (68) 1982-2015 CTN: 420 (354)
PTNMS: 136 (116)
PTNTu: 8 (7)
RFT 57 (54) 42-89 (64) 1975-1989 CTN: 51 (50)
PTNMS: 6 (4)
GR 27 (27) 55-84 (65) 1982-1985 CTN: 25
Cryolysis 222 (158) 21-84 (63) 1977-1991 CTN: 138 (196)
PTNMS: 20 (26)
PDRF peripheral branches 58 (42) 36-85 (58) 2010-2015 PHTN: 39 (30)
PPTTN: 19 (12)
Total 1197 (1041) 18-94 (65) - -
MVD: Microvascular decompression, CPA: cerebello-pontine angle, PBC: Percutaneous Balloon microcompression, RFT: Radiofrequency Thermocoagulation, GR:
Glucerol rhizolysis, PDRF: Pulse-Dose Radiofrequency.
CTN: Classical trigeminal neuralgia, PTNMS: Painful trigeminal neuropathy attributed to multiple sclerosis, PTNTu: Painful trigeminal neuropathy attributed to tumor,
PHTN: Post-herpetic trigeminal neuropathy, PPTTN: Painful post-traumatic trigeminal neuropathy.
Table 1: Personal series: patients operated on and/or followed up by the author at the Neurosurgical Department of the University and at the Pain
Therapy Division of the Molinette Hospital in Turin.
Pathophysiological Basis of Surgical Treatment
The pathophysiological basis of the surgical treatment relies on our
knowledge about the pathophysiology of trigeminal neuralgia. It has
been extensively studied mainly in classical trigeminal neuralgia
[14-18]. The growing knowledge about the mechanisms of neuropathic
pain has clarified the pathophysiology of the painful trigeminal
neuropathies too [19].
Figure 2: Pathophysiology of classical trigeminal neuralgia.
According to most of the Authors, the pathophysiology of CTN is a
process following different steps (Figure 2). The first step is a damage
to the central myelin of the trigeminal fibers either in the dorsal root
entry zone (by neurovascular conflict or cerebello-pontine angle
tumors) or in the pons (by multiple sclerosis plaque). The second step
is the production of “ephapsys”, allowing that tactile, proprioceptive,
and thermal stimuli conveyed by the damaged myelinated fibers be
transmitted to the pain fibers.
The third step is the sensitization of the trigeminal neurons,
chronically “fired” by this exaggerated number of painful stimuli.
These neurons become hyperexcitable and the process of peripheral
and central sensitization progresses (fourth step). Following the
individual threshold, having a high inter- and intra-individual
variability, the hyperexcitable trigeminal neurons can be activated by
further non-painful stimuli and they respond by a simil-epileptic
discharge, causing the painful attacks. As the trigeminal damage
progresses the paroxysmal attacks subside to the prolonged
neuropathic pain and the fifth step is likely to be achieved: a self-
sustaining centralization of pain.
According to this schematization the pathophysiological bases of
the surgical treatment are summarized in the (Figure 3).
Figure 3: Pathophysiological bases of the Surgical Treatment
The surgical removal of offending vessels (and tumors) from the
posterior trigeminal root blocks this process at its first step. A
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progressive damage to the root is prevented and a natural repair of the
damaged trigeminal fibers is allowed in most cases. The patient can be
cured from his CTN, without additional damage to the trigeminal
nerve. CTN recurs only in case of either self-sustaining central
sensitization of trigeminal neurons or a new conflict.
Percutaneous techniques on the gasserian ganglion act at the second
step of the CTN pathophysiological process, producing a suitable
limited deafferentation of the trigeminal root. Balloon compression
and glycerol rhizolysis could selectively destroy the damaged large
myelinated fibers originating the ephapsys. In fact the large A
myelinated fibers, mainly if damaged, are more sensitive to the
ischemic or chemical damage than the small B or C pain fibers [20,21].
The painful attacks can be abolished without significant sensory
deficits. CTN can recur if either the etiological factors (neurovascular
conflict, tumors, multiple sclerosis) produce further damage to the
residual fibers or a self-sustaining central sensitization is just present.
Radiofrequency thermocoagulation could selectively destroy the
smaller B and C pain fibers involved by the ephapsys, because they are
more sensitive to the heating than the A fibers [22,23]. The painful
attacks can be abolished producing only minimal sensory deficits
(hypo or analgesia) involving the pain fibers serving the trigger area.
Again CTN can recur due to either a further damage to the residual
fibers or a self-sustaining central sensitization.
Radiosurgery probably acts at the second step also, by destroying
part of the trigeminal fibers. We do not know yet if there is some kind
of specific vulnerability either of the damaged large myelinated fibers
or of the smaller pain fibers.
The PTN cases present very different kinds of damage to the
trigeminal nerve depending on the different diseases.
In PTN attributed to MS plaque or cerebello-pontine angle slowly
growing tumors the pathophysiological mechanisms are very similar. A
light demyelinization of the large fibers in the trigeminal REZ is
produced by the MS plaque or the compressive effects of the tumor.
Actually the clinical presentation is often the same as in CTN. In MS
cases the progression of the disease can produce a more severe damage
leading to an increasing loss of trigeminal fibers. The same phenomena
are caused by the tumor growth. The heavier damage to the trigeminal
nerve is indicated by the clinical picture showing the appearance of the
atypical findings: mainly spontaneous paroxysms, prolonged pain after
paroxysms, evident sensory deficits, neurovegetative phenomena, and
resistance to the antiepileptic drugs. The mechanisms of peripheral
neuropathic pain are ignited: ectopic activity, peripheral and central
sensitization [19].
The surgical treatment should be chosen on the basis of the degree
of the deafferentation as shown nowadays mainly by the clinical
picture. If the CTN typical findings are prevalent the neuroablative
percutaneous procedures or stereotactic radiosurgery are indicated. As
far as the atypical findings are more severe the choice should be driven
to the neuromodulation procedures. In the cases of cerebollo-pontine
angle or more anterior skull base tumors the surgical removal of the
lesion is mandatory, wherever is possible.
In the post-herpetic and post-traumatic trigeminal neuropathy, the
damage to the peripheral fibers is heavier and the mechanisms of
neuropathic pain are progressing quickly. The clinical picture is
dominated by the atypical findings. In these cases neuroablative
procedures making further trigeminal deafferentation are not
indicated, being useless and at risk of worsening pain. The
neuromodulative procedures have to be chosen.
Microvascular decompression
The first observations on the compression of the trigeminal root by
an artery or tumors as possible cause of TN have been made by Dandy
during his approach to the cerebello-pontine angle for trigeminal
rhizotomy [24]. But it was only with the introduction of the surgical
microscope and the extensive experience of Jannetta [25] that the
importance of the neurovascular conflict as a cause of trigeminal
neuralgia (as well as of other cranial nerves dysfunction) was
recognized and his technique widely accepted [26].
Surgical technique
The patient is positioned in park-bench or lateral position, with the
head flexed and tilted of about 10° toward the floor. A round or
triangular small retromastoid craniectomy, exposing the inferior
border of the transverse sinus and the posterior border of the sigmoid
sinus, is performed. The dura is opened in a reversed “Y” or round flap
and the borders suspended. By allowing generous drainage of the
cerebrospinal fluid the cerebellar hemisphere is gently moved away
from the tentorium and the petrous bone. Following the angle between
tentorium and the petrous bone via a supracerebellar route the Dandy
vein and then the trigeminal root is reached. The careful dissection of
the arachnoid around the trigeminal root from its entry in the pons to
its exit in the porus trigemini allows to show in about 95% of cases one
or more offending arteries and/or veins. The arteries are carefully
dissected from the root and kept far from it spontaneously. A non-
absorbable (Teflon, Goretex) or absorbable (oxidized cellulose, fibrin
glue) materials are then interposed between the artery/arteries and the
pons. In most favourable situations an offending superior cerebellar
artery or its branches can be translated between the Dandy vein and
the tentorium. In rare cases more complicated techniques requiring the
suspension of the offending artery to the tentorium or the petrous
bone dura by stitches are needed. Veins are either dissected or, if
possible, coagulated and sectioned.
Results
Following the data of the published series [1,27-29] (Table 2), the
painful attacks are immediately abolished in 80-98% of cases (mean:
92%). A long-term success is reported in 62-89% of cases (mean 77%)
at 5-11 years. In two series the actuarial curve at more than 10 years
has been calculated, resulting that 70% of patient are free from pain
(without needing medications) at 10 years [30] and 73% at 15 years
[31] and remain essentially stable later. Severe complications from
vascular accidents in the cerebellum or brainstem and leading to severe
neurological deficits or death are reported in 0-1% of cases. Definitive
deficits of the VIII, VII, IV cranial nerves appears in 0-5% of cases.
Sensory deficits in the face are rare and usually mild (2-15% of cases)
and also dysesthesias (>1%).
Percutaneous techinques
These techniques allow producing a suitably discrete lesion in the
retrogasserian portion of the trigeminal root. Techniques and results
have been summarized in recent revues [1,27-29,32,33] (Table 2).
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Patients outcomes
%min-max (mean)
MVD RFT GR PBC SRS
Initial pain relief 80-98 (92) 81-99 (94) 42-98 (75) 82-100 (96) 75-92 (80)a
Long-term pain relief b 62-89 (77) 20-93 (60) 18-59 (38) 54-91 (67) 46-65 (50)
Facial hypoesthesiac 2-15 5-98 (40) 1-29 20-35 10-42
Facial dysesthesiac 0-1 1-12 0.7-12 1.5-5 0-4
Anesthesia dolorosac 0 0-2 0-3 0 0
Corneal sensory lossc 0 1-20 0-5 rare rare
Masticatory weaknessc 0 3-29 0-4 0-10 rare
Diplopiac 0-1 0-1 0-0.2 0-1 rare
Hypoacusiac 0.8-5 0 0 0 rare
Major neurolgical deficitsc 0-1 0 0 0 0
Mortality 0-1 >1/1000 0 >2/1000 0
MVD: Microvascular decompression. RFT: Radiofrequency thermocoagulation. GR: Glycerol rhizolysis. PBC: Percutaneous microcompression. SRS: Stereotactic
radiosurgery.
aPain relief within 1 year from the procedure. bMean values of long-term pain relief are calculated at least at 5 years from the procedures. cDefinitive neurological
deficits.
Table 2: Patients outcomes after different surgical procedures for TN.
Surgical Technique for Approaching the Meckel’s Cave
The trigeminal root is reached by a needle or trocar. It is introduced
following the Hartel’s technique trough the face into the foramen ovale
and then in the gasserian ganglion. The patient lies supine with the
head extended under heavy sedation with intravenous anaesthetic
agents and opioids. General anaesthesia is nowadays rarely required.
The needle is inserted in the check 2.5-3 cm aside from the oral
commissure, then directed in the sagittal plane toward a point lying
2-3 cm anterior to the external auditory meatus along the orbital-
tragus line and in the frontal plane toward a point lying along the
midline or the medial line of the pupil on the supraciliar arcade or the
inferior margin of the orbit. The skull base is reached hopefully against
the pterygoid process. The position of the needle is checked by
fluoroscopy. In lateral projection the tip of the needle should be
directed toward the angle between the superior margin of the petrous
bone and the dorsum sellae. In more difficult cases or during the
learning period an Edgart projection showing the phoramen ovale or
the neuronavigation technique can be used. The entrance in the
phoramen ovale is preceded by a brief contraction of the masticatory
muscles due to the irritation of the trigeminal motor root by the
needle. Then a characteristic loss of resistance because the needle tip is
trespassing the nerve is felt. The penetration should be immediately
stopped. The needle tip position checked by a lateral fluoroscopy and
subsequent movements in the Meckel’s cave done after the sharp stylet
is removed and a blunt stylet inserted.
Radiofrequency thermolesion
The Radiofrequency controlled thermolesion (RFT) has been the
first percutaneous technique introduced for avoiding the high risk of
excessive damage to the trigeminal root caused by the alcohol or
phenol injection in the Meckel cave or the uncontrolled
electrocoagulation of the trigeminal root [22]. It has been the most
widely used percutaneous technique. It is still nowadays the preferred
procedure by the anaesthesiologists dedicated to the trigeminal pain
therapy. The high sensitivity of the small fibers to the heat prevent its
use in the TN cases where the pain affects the first branch, due to the
high risk of the corneal reflex loss and of the neuroparalytic cheratitis.
Difficulties in a correct positioning of the thermoelectrode in scarcely
collaborating patients can prevents an effective but discrete lesion be
produced.
Surgical technique
After the phoramen ovale has been cannulated, an electrode is
introduced through the needle up in the root. The patient is awakened
from the sedation. By a gentle electrostimulation facial paresthesias
that the patient can refer and/or muscular contractions (trigemino-
facial reflexes) are produced and allow to position the tip of the
electrode between the fibers coming from the trigger area. Then the
patient is sedated again and radiofrequency thermocoagulation is
produced in a first step by 60-70°C applied during “30-60”. The
procedure is repeated in other steps and stopped when an analgesia
associated to light tactile hypoesthesia is obtained in the trigger area.
Results
Immediate abolition of the painful attacks is obtained in 81-99% of
patients (mean 94%). Long-term abolition is obtained in 20-93% of
cases, with a mean of 60% of cases at 5 years. Hypo- or anesthetic areas
in the face remains in 5-98% (mean 40% of cases), most often mild.
Major dysesthesias affect 1-12% of patients, and anesthesia dolorosa
0-2% of cases. Corneal sensory impairment has been found in 1-20%,
and it caused a keratytis in 0.6-3% of cases. Masticatory muscles
weakness is reported in 3-29% of cases, and diplopia in 0-1%. Mortality
is less than 1 in every 1,000 cases, due to carotid lesion.
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Glycerol rhizolysis
Introduced by Hakanson [34] the glycerol rhizolysis (GR) has been
and is nowadays the less used percutaneous technique, in spite of its
theoretical advantages of automatically finding and selectively
destroying the large damaged trigeminal fibers, and then abolishing
the pain without significant neurological deficits. But it is not easy to
perform correctly because of the impossibility either to get the
gasserian ganglion cystern or to measure exactly the quantity of
glycerol to be injected.
Surgical technique
The GR is performed by introducing the needle in the gasserian
cistern. The patient is in sitting position with the head flexed and
rotated toward the affected side. The needle tip is pushed up until the
cerebrospinal fluid come from the needle. Then a hydrosolic contrast
medium is injected under radiographic control. The operator knows
that he is in the correct spot when a radiographic image of the
gasserian cistern is obtained. The contrast medium is withdrawn and a
similar volume of glycerol is injected (usually 0.2-0.4 ml) and left in the
cistern for few minutes. Some operator inject small doses of glycerol,
checking the touch and pinprick sensation in the patient face, then
stop the procedures when light hypoesthesia is obtained in the painful
area. This procedure cannot be performed correctly if the gasserian
cistern is not viable, like in patients with previous percutaneous
procedures in the gasserian ganglion [35,36].
Results
An immediate abolition of pain is obtained in 42-98% of cases
(mean: 75%), and long-term effects in 18-59% of cases (mean 38%).
Persistent severe hypoesthesia remains in 1-29% of cases and major
dysesthesias affect 0.7-12% of patients. Anesthesia dolorosa, corneal
sensory loss, and diplopia are infrequent. Masticatory weakness is rare
(0-4%). No intraoperative deaths have been reported.
Balloon microcompression
It was introduced by Mullan [37]. Among the percutaneous
techniques, balloon microcompression (PBC) is the easier and less
time consuming to perform correctly and does not require any patient
collaboration. As in the GR the theoretical high sensitivity of the large
damaged myelinated fibers to the compression could allow to
automatically find and selectively destroying them, sparing the
undamaged large fibers and more the small fibers. In this way the effect
on the pain can be obtained without significant sensory deficits. Then
this technique can be applied more safely to the TN involving the first
trigeminal branch and with more chances of controlling the TN
involving more than one trigeminal division territories.
Surgical technique
The PBC is performed by a 14 gauge trocar to reach the Meckel’s
cavum. Then a Fogarty 4 French is introduced until its tip having the
gonflable balloon exits from the needle. Under radiographic control in
lateral projection the balloon is filled by hydrosolic contrast medium
until it assumes a “pear-shaped” image (usually with 0.5-0.7 ml of
contrast medium). The compression is maintained during about 1’.
Sometime only an “oval-shaped” inflation of the balloon can be
obtained also with the maximum volume of 1 ml. This can mean that
the tip of the catether is outside the Meckel’s cave in the subtemporal
arachnoidal space. A more correct positioning drawing back the
catheter tip inside the Meckel’s cave can allow to obtain the pear-
shaped inflation. Sometime the balloon remains “oval-shaped” and this
means that the patient’s Meckel’s cave is too wide, the trigeminal root is
atrophic, or the dura covering of the cave has been lacerated. In these
cases prolonging the compression to 2-3 minutes or more can be
useful. An effective compression of the trigeminal root is indicated by
ipsilateral conjunctival chemosis arousing from an inhibition of the
sympathetic contingent directed to the eye. A trigemino-cardiac reflex
causing baradicardia is also a good sign of effective compression. It can
arise also at the penetration of the trocar in the trigeminal ganglion.
The anaesthesiologist should be aware of this and administer Atropine
as needed to correct the bradicardia and prevent dangerous cardiac
arrest.
Results
Painful attacks are immediately abolished in 82-100% of cases
(mean 96%). Long-term effect has been found in 54-91% of cases
(mean 67%), with a rate of recurrence at 5 years between 20 and 30%.
Postoperative facial numbness is present in most of the patients, but
often resolves within 3 months [38]. Stable sensory deficits, usually
mild, remain in 20-35% of patients. The rate of dysesthesias is between
1.5% and 5%, and decreases with the decreasing compression time.
Anesthesia dolorosa, loss of corneal reflex, and keratitis are
exceptional. Postoperative masseter and masticatory muscles weakness
is common, but in about 90-95% of cases resolves within few weeks or
months [39,40]. Mortality is less than 2 every 1,000 cases, due to
carotid lesion.
Stereotactic radiosurgery
After the first experience of Leksell [41], at the end of the 1990’s the
MRI visualization of the trigeminal root has allowed to precisely define
a beam for its stereotactic irradiation. Then the treatment of TN by
Stereotactic Radiosurgery (SRS) has been growing exponentially, being
the least invasive neuroablative procedure for TN.
Technique
Under the guide of MRI or High Definition CT scan, SRS is
performed either by Gamma Knife [42], requiring the positioning of a
stereotactic frame, or, more recently, by Cyberknife [43], not requiring
the stereotactic frame. The target is usually chosen in the cysternal
portion of the trigeminal root, between 2 and 14 mm anterior to the
emergency of the nerve from the pons. The dose used varies from 60 to
90 Gy, with best effects obtained by doses between 80 and 90 Gy.
Results
As indicated in the four more recent and with a wider patients
population reports [44-47] (Table 2), the effect on pain is usually
obtained after a mean of 1-6 months after the treatment. Mean follow-
up is between 21 and 44 months. Early pain free patients (at 6 moyhs-1
year) are 75-92%, at 5 years 46-65% (mean 50%). Sensory deficits,
usually mild, remain stable in 10-42% of patients, and major
dysesthesias appear in 0-4%. Infrequently masticator weakness,
diplopia, and decreasing hearing are reported. Higher radiation doses
and treating longer segments of the trigeminal nerve has been
identified as the cause of increased side effects [48]. Repeated
radiosurgery is associated with a slightly decreasing pain relief and
increasing facial numbness.
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Indications of surgical treatments
Nowadays a large consensus about the indications of the surgical
treatment of TN has been achieved between Neurologists, Pain
Therapists and Neurosurgeons [29,49,50] (Figure 4). This in spite of a
well-recognized need for further studies better fulfilling the criteria of
evidence based medicine [51].
Figure 4: First line surgical treatment of TN with pure or prevalent
typical clinical findings and its recurrences.
Surgical treatment of TN is indicated when the following
criteria are satisfied:
A well-established clinical diagnosis of CTN has been made. This is
usually easy, but in cases of either some inveterate neuralgia bearing
atypical features (prolonged and burning pain, sensory deficits, etc.) or
patients that is not able to adequately report the characters of their
painful attacks. Most of the Authors agree that the surgical treatment is
not indicated when atypical findings are prevalent. This is mainly the
case of PTN. Actually in these cases the results are quite disappointing
and the risk of collateral effects (deafferentation pain) is high.
Therefore the neuromodulation procedures should be considered.
TN is disabling, that is it affects the patient by frequent painful
attacks without prolonged remission periods, in spite of a correct
pharmacological treatment.
The pharmacological treatment is not effective at well tolerated
doses, that is the pain is not sufficiently controlled and/or the collateral
effects of the drugs does affect the quality of life by marked asthenia,
cognitive deterioration, instability, gastrointestinal and blood cells
disorders.
Most of the Authors agree that the surgical treatment should be
proposed early in the history of the disease, to prevent an irreversible
damage of the trigeminal fibers and a central self-sustaining
sensitization of trigeminal neurons, both causing recurrences of pain
attacks after the surgical treatment. Furthermore early surgery relieves
the patients from avoidable sufferings.
Due to the different etiology of TN, any patient should undergo a
correctly performed MRI study at the beginning of the disease, to
define an “Etiology established TN”. This could be achieved in 100% of
cases when the cause of TN is multiple sclerosis, cerebello-pontine
angle tumors, cavernomas of the pons, aneurysms and arteriovenous
malformations. This is not the case of the neurovascular conflict. Only
the reports utilizing high-resolution MRI and performed by expert
neuroradiologists with special sequences can correctly visualize the
conflict in 84-96% of cases [52,53]. Sensitivity and specificity is much
lesser in most of the current available MRI examinations. Therefore the
neurosurgical decision should be made firstly following the clinical
diagnosis of CTN and patients with eventually negative MRI surgically
explored for a highly probable neurovascular conflict. On the other
hand patients with not well established diagnosis should not be
operated on also if they show an “apparent” positive MRI.
The further step is to choose the first surgical treatment that has to
be used in any specific case.
MVD is the treatment of choice in patients being good surgical
candidates, that is they are less than 70-75 years old without significant
systemic diseases (grade 1 of American Society of Anesthesiology
scale). This procedure assures the best long-term results without
damaging the trigeminal root. The surgical risks are minimal in
experienced hands.
Percutaneous techniques are indicated in poor surgical candidates:
patients more than 70-75 years old or affected by significant systemic
diseases (ASA 2-3). They are indicated also in patients with multiple
sclerosis and in patients with not surgically removable tumors
compressing the trigeminal root. The choose of the percutaneous
technique largely depends on the surgeon’s experience. A well
conducted RFT is the procedure offering the best long-term results. GR
gives a relatively less probabilities of short and long-term results on
pain, but has few risks of post-operative marked sensory deficits if the
glycerol injection is prudentially graduated. PBC is the easiest to
perform in the correct way, gives less distress to the patient and
guarantees results on pain quite as good as the RFT, with less risks of
marked sensory deficits, mainly when neuralgia affects the first
trigeminal division. The results may be disappointing in patients with a
wide Meckel’s cave.
SRS is reaching satisfying results, but not yet so good as the results
of RFT and PBC. The main drawback is the late appearance of its effect
on pain, sometime of few months, unacceptable for patient in severe
pain because of a drug-resistant TN. Furthermore many
Radiotherapists utilize low doses of radiations for safety reasons, and
this can lower the long term effects of the procedure. In any case SRS is
until now the newest and most attractive neuroablative procedure.
When a recurrence of painful attacks appears the pharmacological
treatment is restarted. Again only if it becomes ineffective at tolerable
doses the surgical treatment should be reconsidered.
In case of recurrence after MVD a new exploration of the trigeminal
root in posterior fossa can be performed, to rule out that an
incomplete decompression has been performed at the first operation.
This is the case, for instance, when the pain recurs early. In late
recurrences the decision is more difficult, because late re-explorations
offers more technical difficulties due to thick arachnoidal adhesions
surrounding the trigeminal root, mainly if the Teflon has been used.
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This increases the risk of surgical damage to the trigeminal root and
the nearby positioned cranial nerves. In this case most of the Authors
prefer to choose a percutaneous techniques or SRS.
In case of recurrence after percutaneous techniques or SRS it is
important to consider if a facial hypoesthesia is still present. When no
or only slight sensory deficits are detectable, the same or another
percutaneous procedure can be repeated. Also Radiosurgery option
can be considered. If a marked sensory deficit is still present MVD
should be considered. The increased surgical risk often overcomes the
risk of a deafferentation neuralgia caused by repeated neuroablative
procedures. Also in patients with multiple sclerosis in quite good
general and neurological condition MVD should be offered as a second
option of surgical treatment of TN, mainly if MRI is positive for
neurovascular conflict. Actually some experience has shown good
results, because vascular conflict can be an additional cause of their
TN [54].
Conclusions
The surgical treatment is often curative in most of the patients
affected by invalidating TN, not controlled by a well-tolerated
pharmacological treatment. The surgical risk either of trigeminal
damage (and consequent deafferentation trigeminal neuralgia) or
significant neurological and general complications is very low using
the modern techniques in experienced hands.
The surgical options should be offered to the patients with pure or
prevalent typical clinical findings of TN and performed early in the
natural history of the disease, either to improve the quality of life than
to avoid an irreversible damage to the trigeminal root and a self-
sustaining sensitization of trigeminal neurons. On the other hand
surgery should be cautiously considered as much as the atypical
clinical findings are evident.
MVD is the first choice treatment in case of CTN patients in good
general conditions, giving the best chance that the pain is abolished all
along their life without any neurological deficit. Percutaneous
techniques and Stereotactic Radiosurgery are the first choice treatment
in PTN attributed to MS or tumor and in CTN patients at risk for
major surgery. These procedures allow to reach a satisfying percentage
of patient with their pain abolished without or with minimal
trigeminal sensory deficits.
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